[
    "{\"step_by_step_thinking\": \"To determine if ocrelizumab is effective for primary progressive multiple sclerosis (PPMS), we need to analyze the information provided in the relevant documents. Document [0] states that ocrelizumab significantly reduced the risk of \u2265 12-week confirmed disability progression in patients with PPMS. Document [2] mentions that ocrelizumab demonstrated efficacy in the treatment of PPMS and is the first therapy approved for patients with PPMS. Document [3] also confirms that ocrelizumab reduced measures of clinical and MRI progression in patients with PPMS. Additionally, Document [9] states that ocrelizumab is the only disease-modifying therapy approved for PPMS. Based on this information, we can conclude that ocrelizumab is effective for primary progressive multiple sclerosis (PPMS).\", \"answer_choice\": \"A. yes\"}"
]